Answer of the Day for Jul 28, 2021

By AOTD
Q Icon

Evidence from PRE-CLINICAL studies suggests THC, CBD and nabiximols improve multiple sclerosis (MS) associated symptoms of tremor, spasticity and inflammation. Has the utility of cannabinoids for MS symptoms been evaluated in CLINICAL STUDIES?

See the Answer

Answer of the Day for Jul 27, 2021

By AOTD
Q Icon

Available evidence from human clinical studies suggests that marijuana (limited evidence) and prescription cannabinoid-based medicines (dronabinol) may increase appetite and caloric intake, and promote weight gain in patients with HIV/AIDS. Has the use of cannabinoid-based medicines in cancer or anorexia nervosa been evaluated, too?

See the Answer

Answer of the Day for Jul 26, 2021

By AOTD
Q Icon

Evidence from observational studies and clinical studies suggests that marijuana (limited evidence) and prescription cannabinoids (e.g. dronabinol, nabilone, or nabiximols) may be useful in alleviating one or several co-occurring symptoms often experienced by patients in the palliative care setting. What are some of these palliative care setting symptoms?

See the Answer

Answer of the Day for Jul 25, 2021

By AOTD
Q Icon

PRE-CLINICAL studies show that certain cannabinoids (THC, CBD, THCV, CBDV) and cannabinoid acids (THCA and CBDA) suppress acute nausea and vomiting. Do PRE-CLINICAL studies also show that those same cannabinoids and cannabinoid acids suppress anticipatory nausea?

See the Answer

Answer of the Day for Jul 24, 2021

By AOTD
Q Icon

What is Rimonabant (Acomplia® from Sanofi-Aventis)?

See the Answer

Share The Answer of the Day with colleagues and friends…

Learn something every day® in your Twitter feed…



TheAnswerPage Announces Our New CBD in Clinical Care Course

CBD in Clinical Care Course Image

Learn More

error: Content is protected !!